Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

7033 Background: FLT3-ITD mutant AML is associated with poor prognosis. Our group identified sorafenib (S) as potent inhibitor of FLT3-ITD AML. We demonstrated increased preclinical activity of S w...